• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥瑞珠单抗治疗多发性硬化后引发机化性肺炎:病例报告。

Organizing pneumonia following ocrelizumab use in a patient with multiple sclerosis: A case report.

机构信息

Clinic of Chest Diseases, İstanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Türkiye.

Clinic of Chest Diseases, Başakşehir Çam and Sakura City Hospital, İstanbul, Türkiye.

出版信息

Tuberk Toraks. 2023 Mar;71(1):107-111. doi: 10.5578/tt.20239913.

DOI:10.5578/tt.20239913
Abstract

Ocrelizumab is an anti-CD20 monoclonal antibody used in the treatment of primary progressive and relapsing multiple sclerosis (MS). Although cases of organizing pneumonia have been reported in association with other antiCD20 agents such as rituximab, there is insufficient data in the literature on Ocrelizumab-associated lung involvement. Herein, we present a case of organizing pneumonia in a 37-year-old female patient with multiple sclerosis following Ocrelizumab use.

摘要

奥瑞珠单抗是一种用于治疗原发性进行性和复发性多发性硬化症(MS)的抗 CD20 单克隆抗体。虽然已经报道了与其他抗 CD20 药物(如利妥昔单抗)相关的机化性肺炎病例,但关于奥瑞珠单抗相关肺受累的文献数据不足。在此,我们报告了一例奥瑞珠单抗治疗后发生机化性肺炎的 37 岁女性多发性硬化症患者。

相似文献

1
Organizing pneumonia following ocrelizumab use in a patient with multiple sclerosis: A case report.奥瑞珠单抗治疗多发性硬化后引发机化性肺炎:病例报告。
Tuberk Toraks. 2023 Mar;71(1):107-111. doi: 10.5578/tt.20239913.
2
Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.奥瑞珠单抗换用利妥昔单抗后,多发性硬化症患者首剂后出现迟发性中性粒细胞减少症。
Mult Scler Relat Disord. 2020 Aug;43:102155. doi: 10.1016/j.msard.2020.102155. Epub 2020 May 13.
3
Ocrelizumab and Other CD20 B-Cell-Depleting Therapies in Multiple Sclerosis.奥瑞珠单抗和其他多发性硬化症的 CD20 耗竭疗法。
Neurotherapeutics. 2017 Oct;14(4):835-841. doi: 10.1007/s13311-017-0557-4.
4
Ocrelizumab in highly disabled progressive multiple sclerosis patients.奥瑞珠单抗治疗重度残疾的进展性多发性硬化症患者。
Mult Scler Relat Disord. 2024 Feb;82:105345. doi: 10.1016/j.msard.2023.105345. Epub 2023 Dec 8.
5
Babesia microti infection in a patient with multiple sclerosis treated with ocrelizumab.一名接受奥瑞珠单抗治疗的多发性硬化症患者感染微小巴贝斯虫。
Mult Scler Relat Disord. 2021 Feb;48:102731. doi: 10.1016/j.msard.2020.102731. Epub 2021 Jan 3.
6
Viral pericarditis following ocrelizumab in a multiple sclerosis patient.奥瑞珠单抗治疗多发性硬化症患者后并发病毒性心包炎。
Neurol Sci. 2023 Aug;44(8):2947-2949. doi: 10.1007/s10072-023-06782-0. Epub 2023 Apr 25.
7
Ocrelizumab for the treatment of multiple sclerosis.奥瑞珠单抗治疗多发性硬化症。
Expert Rev Neurother. 2019 Feb;19(2):97-108. doi: 10.1080/14737175.2019.1561284. Epub 2018 Dec 28.
8
Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis.奥瑞珠单抗治疗复发缓解型多发性硬化症后发生急性胰腺炎。
Mult Scler Relat Disord. 2020 Oct;45:102381. doi: 10.1016/j.msard.2020.102381. Epub 2020 Jul 7.
9
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.奥瑞珠单抗输注在复发型和原发进展型多发性硬化症患者中的应用经验:来自 III 期随机 OPERA I、OPERA II 和 ORATORIO 研究的结果。
Mult Scler Relat Disord. 2019 May;30:236-243. doi: 10.1016/j.msard.2019.01.044. Epub 2019 Jan 28.
10
B cell depletion in the treatment of multiple sclerosis.B 细胞耗竭在多发性硬化症治疗中的应用。
Expert Opin Biol Ther. 2019 Mar;19(3):261-271. doi: 10.1080/14712598.2019.1568407. Epub 2019 Jan 23.

引用本文的文献

1
Secondary Organising Pneumonia Among Immunocompromised Multiple Sclerosis Patients Treated With Ocrelizumab Following COVID-19 Infection: Two Case Reports With Literature Review.COVID-19感染后接受奥瑞珠单抗治疗的免疫功能低下多发性硬化症患者中的继发性机化性肺炎:两例病例报告及文献综述
Respirol Case Rep. 2025 Jul 9;13(7):e70268. doi: 10.1002/rcr2.70268. eCollection 2025 Jul.
2
Ocrelizumab-induced organizing pneumonia in multiple sclerosis: case report and literature review.奥瑞珠单抗诱发的多发性硬化症相关性机化性肺炎:病例报告及文献综述
Arch Clin Cases. 2024 Jul 16;11(2):69-73. doi: 10.22551/2024.43.1102.10291. eCollection 2024.

本文引用的文献

1
Ocrelizumab: a new milestone in multiple sclerosis therapy.奥瑞珠单抗:多发性硬化症治疗的一个新里程碑。
Ther Adv Neurol Disord. 2018 May 10;11:1756286418773025. doi: 10.1177/1756286418773025. eCollection 2018.
2
Radio-pathological correlation of organizing pneumonia (OP): a pictorial review.机化性肺炎(OP)的放射学与病理学相关性:图文综述
Br J Radiol. 2017 Mar;90(1071):20160723. doi: 10.1259/bjr.20160723. Epub 2017 Feb 17.
3
Rituximab-induced interstitial lung disease: five case reports.利妥昔单抗诱发的间质性肺病:5例病例报告
Eur Clin Respir J. 2015 May 21;2. doi: 10.3402/ecrj.v2.27178. eCollection 2015.
4
Clinical and radiologic distinctions between secondary bronchiolitis obliterans organizing pneumonia and cryptogenic organizing pneumonia.继发性闭塞性细支气管炎机化性肺炎与隐源性机化性肺炎的临床及影像学鉴别
Respir Care. 2009 Aug;54(8):1028-32.
5
Rituximab-induced lung disease: A systematic literature review.利妥昔单抗相关性肺疾病:系统文献回顾。
Eur Respir J. 2010 Mar;35(3):681-7. doi: 10.1183/09031936.00080209. Epub 2009 Jul 16.
6
Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab.抗肿瘤单克隆抗体的上市后安全性:利妥昔单抗和曲妥珠单抗。
Pharmacoepidemiol Drug Saf. 2008 Jul;17(7):714-21. doi: 10.1002/pds.1587.
7
Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.利妥昔单抗治疗非霍奇金淋巴瘤后发生的伴有机化性肺炎的闭塞性细支气管炎。
Hematol Oncol. 2006 Dec;24(4):234-7. doi: 10.1002/hon.799.
8
Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin's lymphoma following R-CHOP and pegylated filgrastim.一名非霍奇金淋巴瘤患者在接受R-CHOP方案及聚乙二醇化非格司亭治疗后发生机化性细支气管炎伴机化性肺炎。
Leuk Lymphoma. 2005 Oct;46(10):1523-6. doi: 10.1080/10428190500144615.
9
Cryptogenic organizing pneumonia.隐源性机化性肺炎
Semin Respir Crit Care Med. 2001 Aug;22(4):449-60. doi: 10.1055/s-2001-17387.
10
Drug-induced bronchiolitis obliterans organizing pneumonia.药物性闭塞性细支气管炎并机化性肺炎
Clin Chest Med. 2004 Mar;25(1):89-94. doi: 10.1016/S0272-5231(03)00140-0.